Structured evidence table for Calcium Bone Mineral Density Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Calcium Bone Mineral Density Randomized Trial | Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Mineral Density Randomized Trial | 18 A landmark review by Plosker and McTavish summarized the pharmacologic and clinical evidence for IN-CAL through the mid-1990s. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Mineral Density Randomized Trial | The present review builds upon this foundation by contextualizing historical data and synthesizing subsequent evidence across 3 domains: (1) pharmacology and mechanisms; (2) established and preventive osteoporosis; and (3) acute orthopaedic applications, with particular emphasis on analgesia and time-dependent therapeutic effects. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Mineral Density Randomized Trial | 1 3 - 4 5 , Intranasal salmon calcitonin (IN-CAL) is a peptide antiresorptive agent historically used in the management of postmenopausal osteoporosis, where early randomized trials demonstrated lumbar spine-specific increases in bone mineral density (BMD) with minimal peripheral effects. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Mineral Density Randomized Trial | Results At the endpoint, serum calcium levels in the intervention group were significantly higher than those in the control group ( p p p Conclusion Although within-group improvements in bone mineral density were observed, no significant differences between groups were detected. | 4 | Rueangsri N (2026) | The effects of dairy products containing <i>Lactobacillus bulgaricus</i> and <i>Streptococcus thermophilus</i> on bone turnover biomarkers and bone mineral density: a pilot trial study. |
| Calcium Bone Mineral Density Randomized Trial | Background/objectives Low bone mineral density is a major public health concern that negatively affects quality of life. | 4 | Rueangsri N (2026) | The effects of dairy products containing <i>Lactobacillus bulgaricus</i> and <i>Streptococcus thermophilus</i> on bone turnover biomarkers and bone mineral density: a pilot trial study. |
| Calcium Bone Mineral Density Randomized Trial | Dairy products fermented with Lactobacillus bulgaricus and Streptococcus thermophilus have been suggested to promote gut health, enhance calcium absorption, and suppress inflammatory cytokines related to bone turnover. | 4 | Rueangsri N (2026) | The effects of dairy products containing <i>Lactobacillus bulgaricus</i> and <i>Streptococcus thermophilus</i> on bone turnover biomarkers and bone mineral density: a pilot trial study. |
Source documents